Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)

NCT04323657 is registered in ClinicalTrials.gov with TCR2 Therapeutics as lead sponsor.

NCT NCT04323657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04323657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
TCR2 Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
March 27, 2020
Completion date
February 24, 2023
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma, non hodgkin lymphoma, primary mediastinal large b cell lymphoma